MXPA00004396A - Azaring-ether derivatives and their use as nicotinic ach receptor modulators - Google Patents
Azaring-ether derivatives and their use as nicotinic ach receptor modulatorsInfo
- Publication number
- MXPA00004396A MXPA00004396A MXPA/A/2000/004396A MXPA00004396A MXPA00004396A MX PA00004396 A MXPA00004396 A MX PA00004396A MX PA00004396 A MXPA00004396 A MX PA00004396A MX PA00004396 A MXPA00004396 A MX PA00004396A
- Authority
- MX
- Mexico
- Prior art keywords
- alkyl
- alkoxy
- cycloalkyl
- alkynyl
- pyridyl
- Prior art date
Links
- 102000034433 acetylcholine receptors Human genes 0.000 title claims abstract description 22
- 230000000051 modifying Effects 0.000 title claims description 20
- 108010009685 Cholinergic Receptors Proteins 0.000 title description 4
- 150000001875 compounds Chemical class 0.000 claims abstract description 90
- -1 methylenedioxy Chemical group 0.000 claims abstract description 63
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 59
- 125000000753 cycloalkyl group Chemical group 0.000 claims abstract description 39
- 125000000304 alkynyl group Chemical group 0.000 claims abstract description 38
- 239000000203 mixture Substances 0.000 claims abstract description 36
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims abstract description 34
- 125000003545 alkoxy group Chemical group 0.000 claims abstract description 33
- 125000000000 cycloalkoxy group Chemical group 0.000 claims abstract description 33
- 229910052736 halogen Inorganic materials 0.000 claims abstract description 33
- 150000002367 halogens Chemical group 0.000 claims abstract description 33
- 239000011780 sodium chloride Substances 0.000 claims abstract description 33
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims abstract description 32
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims abstract description 32
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims abstract description 31
- 230000027455 binding Effects 0.000 claims abstract description 25
- 150000003839 salts Chemical class 0.000 claims abstract description 25
- 108020000715 acetylcholine receptors Proteins 0.000 claims abstract description 18
- 125000003342 alkenyl group Chemical group 0.000 claims abstract description 14
- 125000002911 monocyclic heterocycle group Chemical group 0.000 claims abstract description 14
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims abstract description 13
- 229910052760 oxygen Inorganic materials 0.000 claims abstract description 12
- 229910052717 sulfur Inorganic materials 0.000 claims abstract description 12
- 125000003118 aryl group Chemical group 0.000 claims abstract description 10
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 10
- 239000001257 hydrogen Substances 0.000 claims abstract description 10
- 125000003710 aryl alkyl group Chemical group 0.000 claims abstract description 9
- 125000002950 monocyclic group Chemical group 0.000 claims abstract description 9
- 125000001424 substituent group Chemical group 0.000 claims abstract description 9
- 125000005083 alkoxyalkoxy group Chemical group 0.000 claims abstract description 8
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract description 7
- 125000006569 (C5-C6) heterocyclic group Chemical group 0.000 claims abstract description 6
- 125000002618 bicyclic heterocycle group Chemical group 0.000 claims abstract description 5
- 125000005309 thioalkoxy group Chemical group 0.000 claims abstract description 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims abstract description 4
- 150000002431 hydrogen Chemical group 0.000 claims abstract description 4
- 239000003446 ligand Substances 0.000 claims abstract description 3
- 201000010099 disease Diseases 0.000 claims description 52
- 239000000126 substance Substances 0.000 claims description 20
- 208000002193 Pain Diseases 0.000 claims description 14
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims description 11
- 206010001897 Alzheimer's disease Diseases 0.000 claims description 11
- 230000000694 effects Effects 0.000 claims description 11
- 239000008194 pharmaceutical composition Substances 0.000 claims description 10
- 230000004064 dysfunction Effects 0.000 claims description 8
- 230000000391 smoking Effects 0.000 claims description 8
- 238000007792 addition Methods 0.000 claims description 7
- RWRDLPDLKQPQOW-UHFFFAOYSA-N pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims description 7
- 230000016160 smooth muscle contraction Effects 0.000 claims description 7
- 206010061536 Parkinson's disease Diseases 0.000 claims description 6
- 125000004076 pyridyl group Chemical group 0.000 claims description 6
- 210000003169 Central Nervous System Anatomy 0.000 claims description 5
- 230000004770 neurodegeneration Effects 0.000 claims description 5
- 206010061218 Inflammation Diseases 0.000 claims description 4
- 239000003085 diluting agent Substances 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 230000004054 inflammatory process Effects 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 3
- ZSIQJIWKELUFRJ-UHFFFAOYSA-N Azepane Chemical compound C1CCCNCC1 ZSIQJIWKELUFRJ-UHFFFAOYSA-N 0.000 claims description 2
- 125000004435 hydrogen atoms Chemical group [H]* 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims description 2
- HONIICLYMWZJFZ-UHFFFAOYSA-N Azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 claims 1
- 206010037211 Psychomotor hyperactivity Diseases 0.000 claims 1
- 125000004070 6 membered heterocyclic group Chemical group 0.000 abstract 1
- 229960002715 Nicotine Drugs 0.000 description 29
- 229930015196 nicotine Natural products 0.000 description 26
- SNICXCGAKADSCV-JTQLQIEISA-N Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 23
- 238000002360 preparation method Methods 0.000 description 19
- 239000002253 acid Substances 0.000 description 17
- 102000005962 receptors Human genes 0.000 description 15
- 108020003175 receptors Proteins 0.000 description 15
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 13
- 239000000243 solution Substances 0.000 description 13
- YMWUJEATGCHHMB-UHFFFAOYSA-N methylene dichloride Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 12
- 239000000843 powder Substances 0.000 description 12
- 239000003981 vehicle Substances 0.000 description 12
- 239000007788 liquid Substances 0.000 description 11
- 210000004556 Brain Anatomy 0.000 description 10
- 239000004480 active ingredient Substances 0.000 description 10
- 239000002775 capsule Substances 0.000 description 9
- 230000001713 cholinergic Effects 0.000 description 9
- 230000003287 optical Effects 0.000 description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 239000002904 solvent Substances 0.000 description 9
- 208000008425 Protein Deficiency Diseases 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 239000007787 solid Substances 0.000 description 8
- 239000000725 suspension Substances 0.000 description 8
- 210000001519 tissues Anatomy 0.000 description 8
- 102000019315 Nicotinic acetylcholine receptors Human genes 0.000 description 7
- 108050006807 Nicotinic acetylcholine receptors Proteins 0.000 description 7
- 239000002585 base Substances 0.000 description 7
- UIIMBOGNXHQVGW-UHFFFAOYSA-M buffer Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 206010013754 Drug withdrawal syndrome Diseases 0.000 description 6
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 6
- 239000002552 dosage form Substances 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 239000002858 neurotransmitter agent Substances 0.000 description 6
- 239000008188 pellet Substances 0.000 description 6
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 6
- 206010002855 Anxiety Diseases 0.000 description 5
- 206010057666 Anxiety disease Diseases 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N HCl Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
- 241000700159 Rattus Species 0.000 description 5
- 230000036506 anxiety Effects 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 239000007853 buffer solution Substances 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 230000003291 dopaminomimetic Effects 0.000 description 5
- 210000002569 neurons Anatomy 0.000 description 5
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 4
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 description 4
- 206010003736 Attention deficit/hyperactivity disease Diseases 0.000 description 4
- 206010012735 Diarrhoea Diseases 0.000 description 4
- 206010015037 Epilepsy Diseases 0.000 description 4
- 208000008589 Obesity Diseases 0.000 description 4
- 210000003491 Skin Anatomy 0.000 description 4
- 230000000202 analgesic Effects 0.000 description 4
- 201000006287 attention deficit hyperactivity disease Diseases 0.000 description 4
- 125000004432 carbon atoms Chemical group C* 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 201000008286 diarrhea Diseases 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- NLPRAJRHRHZCQQ-IVZWLZJFSA-N epibatidine Chemical compound C1=NC(Cl)=CC=C1[C@@H]1[C@H](N2)CC[C@H]2C1 NLPRAJRHRHZCQQ-IVZWLZJFSA-N 0.000 description 4
- 238000005755 formation reaction Methods 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 235000020824 obesity Nutrition 0.000 description 4
- 239000006187 pill Substances 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 239000003381 stabilizer Substances 0.000 description 4
- 239000000375 suspending agent Substances 0.000 description 4
- 201000010874 syndrome Diseases 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
- 239000002562 thickening agent Substances 0.000 description 4
- 229960004373 Acetylcholine Drugs 0.000 description 3
- 208000000044 Amnesia Diseases 0.000 description 3
- 206010006550 Bulimia nervosa Diseases 0.000 description 3
- 206010008874 Chronic fatigue syndrome Diseases 0.000 description 3
- 206010010904 Convulsion Diseases 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- 206010020651 Hyperkinesia Diseases 0.000 description 3
- 208000000269 Hyperkinesis Diseases 0.000 description 3
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 3
- 206010027599 Migraine Diseases 0.000 description 3
- 208000008085 Migraine Disorders Diseases 0.000 description 3
- 102000014415 Muscarinic acetylcholine receptor family Human genes 0.000 description 3
- 108050003473 Muscarinic acetylcholine receptor family Proteins 0.000 description 3
- 241000208125 Nicotiana Species 0.000 description 3
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 3
- 229940005483 OPIOID ANALGESICS Drugs 0.000 description 3
- 229920002873 Polyethylenimine Polymers 0.000 description 3
- 241000700157 Rattus norvegicus Species 0.000 description 3
- 206010039966 Senile dementia Diseases 0.000 description 3
- 229940076279 Serotonin Drugs 0.000 description 3
- 206010043118 Tardive dyskinesia Diseases 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N acetic acid ethyl ester Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 3
- 125000004429 atoms Chemical group 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000003086 colorant Substances 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 230000002354 daily Effects 0.000 description 3
- 230000003247 decreasing Effects 0.000 description 3
- 239000002270 dispersing agent Substances 0.000 description 3
- 229960003638 dopamine Drugs 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- BDAGIHXWWSANSR-UHFFFAOYSA-N formic acid Chemical compound OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000001530 fumaric acid Substances 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 239000003365 glass fiber Substances 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- CSNNHWWHGAXBCP-UHFFFAOYSA-L magnesium sulphate Substances [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 3
- 230000001537 neural Effects 0.000 description 3
- 230000003364 opioid Effects 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 229920001601 polyetherimide Polymers 0.000 description 3
- 230000003389 potentiating Effects 0.000 description 3
- 230000002829 reduced Effects 0.000 description 3
- 201000000980 schizophrenia Diseases 0.000 description 3
- 231100000486 side effect Toxicity 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- 229910002027 silica gel Inorganic materials 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 239000012085 test solution Substances 0.000 description 3
- 230000000699 topical Effects 0.000 description 3
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2R,3R,4S,5R,6S)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2S,3R,4S,5R,6R)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2R,3R,4S,5R,6R)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N (E)-but-2-enedioate;hydron Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- JMTMWFZXOIWTLX-UHFFFAOYSA-N 2-pyridin-2-yloxypyridine Chemical class C=1C=CC=NC=1OC1=CC=CC=N1 JMTMWFZXOIWTLX-UHFFFAOYSA-N 0.000 description 2
- 206010000565 Acquired immunodeficiency syndrome Diseases 0.000 description 2
- 208000007848 Alcoholism Diseases 0.000 description 2
- 206010002383 Angina pectoris Diseases 0.000 description 2
- 208000000103 Anorexia Nervosa Diseases 0.000 description 2
- 208000006673 Asthma Diseases 0.000 description 2
- 241000416162 Astragalus gummifer Species 0.000 description 2
- 206010003805 Autism Diseases 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N Benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 206010004939 Bipolar I disease Diseases 0.000 description 2
- 206010004938 Bipolar disease Diseases 0.000 description 2
- 210000003710 Cerebral Cortex Anatomy 0.000 description 2
- 206010057668 Cognitive disease Diseases 0.000 description 2
- 206010009900 Colitis ulcerative Diseases 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N D-sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N DL-phenylalanine Chemical compound OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
- 206010012289 Dementia Diseases 0.000 description 2
- 206010012271 Dementia Alzheimer's type Diseases 0.000 description 2
- 206010012335 Dependence Diseases 0.000 description 2
- FAMRKDQNMBBFBR-BQYQJAHWSA-N Diethyl azodicarboxylate Chemical compound CCOC(=O)\N=N\C(=O)OCC FAMRKDQNMBBFBR-BQYQJAHWSA-N 0.000 description 2
- 206010013932 Dyslexia Diseases 0.000 description 2
- 201000004311 Gilles de la Tourette syndrome Diseases 0.000 description 2
- 229940049906 Glutamate Drugs 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N HEPES Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- 206010021972 Inflammatory bowel disease Diseases 0.000 description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
- GUBGYTABKSRVRQ-UUNJERMWSA-N Lactose Natural products O([C@@H]1[C@H](O)[C@H](O)[C@H](O)O[C@@H]1CO)[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1 GUBGYTABKSRVRQ-UUNJERMWSA-N 0.000 description 2
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 2
- 240000007472 Leucaena leucocephala Species 0.000 description 2
- IWYDHOAUDWTVEP-UHFFFAOYSA-N Mandelic acid Chemical compound OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 2
- 206010026749 Mania Diseases 0.000 description 2
- FEWJPZIEWOKRBE-XIXRPRMCSA-N Mesotartaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-XIXRPRMCSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L MgCl2 Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N Morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
- 206010028403 Mutism Diseases 0.000 description 2
- 210000003928 Nasal Cavity Anatomy 0.000 description 2
- 206010053643 Neurodegenerative disease Diseases 0.000 description 2
- 229960002748 Norepinephrine Drugs 0.000 description 2
- WLJNZVDCPSBLRP-UHFFFAOYSA-N Pamoic acid Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 description 2
- VLTRZXGMWDSKGL-UHFFFAOYSA-M Perchlorate Chemical compound [O-]Cl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-M 0.000 description 2
- VLTRZXGMWDSKGL-UHFFFAOYSA-N Perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
- 208000001293 Peripheral Nervous System Disease Diseases 0.000 description 2
- 206010034606 Peripheral neuropathy Diseases 0.000 description 2
- 208000008348 Post-Concussion Syndrome Diseases 0.000 description 2
- 208000004550 Postoperative Pain Diseases 0.000 description 2
- 206010036596 Premature ejaculation Diseases 0.000 description 2
- 206010036618 Premenstrual syndrome Diseases 0.000 description 2
- 208000000399 Procedural Pain Diseases 0.000 description 2
- 206010052276 Pseudodementia Diseases 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N Salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 206010039911 Seizure Diseases 0.000 description 2
- 206010040984 Sleep disease Diseases 0.000 description 2
- 206010041250 Social phobia Diseases 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N Stearic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- CZMRCDWAGMRECN-GDQSFJPYSA-N Sucrose Natural products O([C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1)[C@@]1(CO)[C@H](O)[C@@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-GDQSFJPYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 208000000323 Tourette Syndrome Diseases 0.000 description 2
- 206010044126 Tourette's disease Diseases 0.000 description 2
- 229940116362 Tragacanth Drugs 0.000 description 2
- 229920001615 Tragacanth Polymers 0.000 description 2
- 208000002271 Trichotillomania Diseases 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N Triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Tris Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 102000015296 acetylcholine-gated cation-selective channel activity proteins Human genes 0.000 description 2
- 108040006409 acetylcholine-gated cation-selective channel activity proteins Proteins 0.000 description 2
- 230000001154 acute Effects 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 201000007930 alcohol dependence Diseases 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 201000002055 autistic disease Diseases 0.000 description 2
- 125000003310 benzodiazepinyl group Chemical class N1N=C(C=CC2=C1C=CC=C2)* 0.000 description 2
- MIOPJNTWMNEORI-UHFFFAOYSA-M camphorsulfonate anion Chemical compound C1CC2(CS([O-])(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-M 0.000 description 2
- 150000004657 carbamic acid derivatives Chemical class 0.000 description 2
- AOGYCOYQMAVAFD-UHFFFAOYSA-M carbonochloridate Chemical compound [O-]C(Cl)=O AOGYCOYQMAVAFD-UHFFFAOYSA-M 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 230000001684 chronic Effects 0.000 description 2
- 235000013985 cinnamic acid Nutrition 0.000 description 2
- 229930016911 cinnamic acid Natural products 0.000 description 2
- 229940110456 cocoa butter Drugs 0.000 description 2
- 235000019868 cocoa butter Nutrition 0.000 description 2
- 230000001149 cognitive Effects 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 235000014632 disordered eating Nutrition 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 201000006180 eating disease Diseases 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 238000001640 fractional crystallisation Methods 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N fumaric acid Chemical compound OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 125000000623 heterocyclic group Chemical group 0.000 description 2
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 2
- 230000004968 inflammatory condition Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 230000029849 luteinization Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 2
- 235000019341 magnesium sulphate Nutrition 0.000 description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-N malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 2
- 229960002510 mandelic acid Drugs 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 229960005181 morphine Drugs 0.000 description 2
- 229930014694 morphine Natural products 0.000 description 2
- 201000003631 narcolepsy Diseases 0.000 description 2
- 230000002232 neuromuscular Effects 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 229940021182 non-steroidal anti-inflammatory drugs Drugs 0.000 description 2
- 201000008430 obsessive-compulsive disease Diseases 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000002093 peripheral Effects 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 230000002335 preservative Effects 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000000069 prophylaxis Effects 0.000 description 2
- 239000000018 receptor agonist Substances 0.000 description 2
- 230000000306 recurrent Effects 0.000 description 2
- 210000002345 respiratory system Anatomy 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000020341 sensory perception of pain Effects 0.000 description 2
- 230000000862 serotonergic Effects 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 230000002459 sustained Effects 0.000 description 2
- 150000003892 tartrate salts Chemical class 0.000 description 2
- 239000000196 tragacanth Substances 0.000 description 2
- 235000010487 tragacanth Nutrition 0.000 description 2
- ZMANZCXQSJIPKH-UHFFFAOYSA-N triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 201000006704 ulcerative colitis Diseases 0.000 description 2
- ZGUNAGUHMKGQNY-UHFFFAOYSA-N α-phenylglycine Chemical compound OC(=O)C(N)C1=CC=CC=C1 ZGUNAGUHMKGQNY-UHFFFAOYSA-N 0.000 description 2
- ANJTVLIZGCUXLD-BDAKNGLRSA-N (-)-Cytisine Natural products C1NC[C@@H]2CN3C(=O)C=CC=C3[C@H]1C2 ANJTVLIZGCUXLD-BDAKNGLRSA-N 0.000 description 1
- WSWCOQWTEOXDQX-MQQKCMAXSA-M (E,E)-sorbate Chemical compound C\C=C\C=C\C([O-])=O WSWCOQWTEOXDQX-MQQKCMAXSA-M 0.000 description 1
- 125000004505 1,2,4-oxadiazol-5-yl group Chemical group O1N=CN=C1* 0.000 description 1
- 125000004507 1,2,5-oxadiazol-3-yl group Chemical group O1N=C(C=N1)* 0.000 description 1
- 125000004508 1,2,5-oxadiazol-4-yl group Chemical group O1N=CC(=N1)* 0.000 description 1
- 125000004518 1,2,5-thiadiazol-3-yl group Chemical group S1N=C(C=N1)* 0.000 description 1
- DDMOUSALMHHKOS-UHFFFAOYSA-N 1,2-dichloro-1,1,2,2-tetrafluoroethane Chemical compound FC(F)(Cl)C(F)(F)Cl DDMOUSALMHHKOS-UHFFFAOYSA-N 0.000 description 1
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 1
- 125000001462 1-pyrrolyl group Chemical group [*]N1C([H])=C([H])C([H])=C1[H] 0.000 description 1
- VUKAUDKDFVSVFT-UHFFFAOYSA-N 2-[6-[4,5-bis(2-hydroxypropoxy)-2-(2-hydroxypropoxymethyl)-6-methoxyoxan-3-yl]oxy-4,5-dimethoxy-2-(methoxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)-5-methoxyoxane-3,4-diol Chemical compound COC1C(OC)C(OC2C(C(O)C(OC)C(CO)O2)O)C(COC)OC1OC1C(COCC(C)O)OC(OC)C(OCC(C)O)C1OCC(C)O VUKAUDKDFVSVFT-UHFFFAOYSA-N 0.000 description 1
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 125000000389 2-pyrrolyl group Chemical group [H]N1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K 2qpq Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 125000003682 3-furyl group Chemical group O1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- 125000001397 3-pyrrolyl group Chemical group [H]N1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
- 125000004539 5-benzimidazolyl group Chemical group N1=CNC2=C1C=CC(=C2)* 0.000 description 1
- 206010000496 Acne Diseases 0.000 description 1
- GTZCVFVGUGFEME-UHFFFAOYSA-N Aconitic acid Chemical class OC(=O)CC(C(O)=O)=CC(O)=O GTZCVFVGUGFEME-UHFFFAOYSA-N 0.000 description 1
- RMRFFCXPLWYOOY-UHFFFAOYSA-N Allyl radical Chemical group [CH2]C=C RMRFFCXPLWYOOY-UHFFFAOYSA-N 0.000 description 1
- 206010060961 Appetite disease Diseases 0.000 description 1
- 206010003119 Arrhythmia Diseases 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 240000008564 Boehmeria nivea Species 0.000 description 1
- 208000001183 Brain Injury Diseases 0.000 description 1
- 241000272079 Bungarus multicinctus Species 0.000 description 1
- UESYMIFUVPHBHL-UHFFFAOYSA-N CC(O)=O.CC(O)=O.CC(O)=O Chemical compound CC(O)=O.CC(O)=O.CC(O)=O UESYMIFUVPHBHL-UHFFFAOYSA-N 0.000 description 1
- 229960004424 Carbon Dioxide Drugs 0.000 description 1
- 206010007521 Cardiac arrhythmias Diseases 0.000 description 1
- 210000001638 Cerebellum Anatomy 0.000 description 1
- 206010009191 Circadian rhythm sleep disease Diseases 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- PXBRQCKWGAHEHS-UHFFFAOYSA-N Dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 1
- 239000004338 Dichlorodifluoromethane Substances 0.000 description 1
- 229940087091 Dichlorotetrafluoroethane Drugs 0.000 description 1
- 206010013663 Drug dependence Diseases 0.000 description 1
- 241000272060 Elapidae Species 0.000 description 1
- 206010014698 Endocrine disease Diseases 0.000 description 1
- 210000002615 Epidermis Anatomy 0.000 description 1
- 241000320517 Epipedobates tricolor Species 0.000 description 1
- 210000003414 Extremities Anatomy 0.000 description 1
- 241000722985 Fidia Species 0.000 description 1
- 229960002989 Glutamic Acid Drugs 0.000 description 1
- MNWFXJYAOYHMED-UHFFFAOYSA-N Heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 1
- 229940120060 Heroin Drugs 0.000 description 1
- GVGLGOZIDCSQPN-PVHGPHFFSA-N Heroin Chemical compound O([C@H]1[C@H](C=C[C@H]23)OC(C)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4OC(C)=O GVGLGOZIDCSQPN-PVHGPHFFSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 201000001971 Huntington's disease Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010020850 Hyperthyroidism Diseases 0.000 description 1
- 206010021654 Increased appetite Diseases 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 208000001456 Jet Lag Syndrome Diseases 0.000 description 1
- SFLSHLFXELFNJZ-MRVPVSSYSA-N L-Noradrenaline Natural products NC[C@@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-MRVPVSSYSA-N 0.000 description 1
- 229940067606 Lecithin Drugs 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L Magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 206010027175 Memory impairment Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 210000002027 Muscle, Skeletal Anatomy 0.000 description 1
- 210000003205 Muscles Anatomy 0.000 description 1
- HOKKHZGPKSLGJE-GSVOUGTGSA-N NMDA Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 description 1
- UZHSEJADLWPNLE-GRGSLBFTSA-N Naloxone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(O)C2=C5[C@@]13CCN4CC=C UZHSEJADLWPNLE-GRGSLBFTSA-N 0.000 description 1
- 229960004127 Naloxone Drugs 0.000 description 1
- 210000000715 Neuromuscular Junction Anatomy 0.000 description 1
- 102000003840 Opioid Receptors Human genes 0.000 description 1
- 108090000137 Opioid Receptors Proteins 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N P-Toluenesulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 206010033666 Panic disease Diseases 0.000 description 1
- 206010034800 Phaeochromocytoma Diseases 0.000 description 1
- 206010056238 Phantom pain Diseases 0.000 description 1
- 231100000614 Poison Toxicity 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 208000005107 Premature Birth Diseases 0.000 description 1
- 208000006399 Premature Obstetric Labor Diseases 0.000 description 1
- 206010036590 Premature baby Diseases 0.000 description 1
- 206010036600 Premature labour Diseases 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 229940075554 Sorbate Drugs 0.000 description 1
- 229940075582 Sorbic Acid Drugs 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 208000005057 Thyrotoxicosis Diseases 0.000 description 1
- CYRMSUTZVYGINF-UHFFFAOYSA-N Trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 1
- FIQMHBFVRAXMOP-UHFFFAOYSA-N Triphenylphosphine oxide Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)(=O)C1=CC=CC=C1 FIQMHBFVRAXMOP-UHFFFAOYSA-N 0.000 description 1
- 231100000611 Venom Toxicity 0.000 description 1
- 210000001048 Venoms Anatomy 0.000 description 1
- 241000271897 Viperidae Species 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K [O-]P([O-])([O-])=O Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000000240 adjuvant Effects 0.000 description 1
- 230000001800 adrenalinergic Effects 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 229930013930 alkaloids Natural products 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
- 230000003042 antagnostic Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 239000002830 appetite depressant Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 239000008135 aqueous vehicle Substances 0.000 description 1
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
- 235000021311 artificial sweeteners Nutrition 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- GMWFCJXSQQHBPI-UHFFFAOYSA-N azetidin-3-ol Chemical compound OC1CNC1 GMWFCJXSQQHBPI-UHFFFAOYSA-N 0.000 description 1
- 230000003542 behavioural Effects 0.000 description 1
- WWIWLTSSHDKOKO-UHFFFAOYSA-N benzenesulfonic acid Chemical class OS(=O)(=O)C1=CC=CC=C1.OS(=O)(=O)C1=CC=CC=C1 WWIWLTSSHDKOKO-UHFFFAOYSA-N 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-M benzoate Chemical compound [O-]C(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-M 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 231100000874 brain damage Toxicity 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 235000011148 calcium chloride Nutrition 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 210000004027 cells Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- KYKAJFCTULSVSH-UHFFFAOYSA-N chloro(fluoro)methane Chemical compound F[C]Cl KYKAJFCTULSVSH-UHFFFAOYSA-N 0.000 description 1
- 210000002932 cholinergic neuron Anatomy 0.000 description 1
- 235000019504 cigarettes Nutrition 0.000 description 1
- 229960003920 cocaine Drugs 0.000 description 1
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 1
- ZPUCINDJVBIVPJ-BARDWOONSA-N cocaine Natural products O([C@@H]1C[C@H]2CC[C@H](N2C)[C@@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-BARDWOONSA-N 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- 231100000876 cognitive deterioration Toxicity 0.000 description 1
- 230000003920 cognitive function Effects 0.000 description 1
- 239000000306 component Substances 0.000 description 1
- 210000003618 cortical neuron Anatomy 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000005712 crystallization Effects 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 description 1
- 229930017327 cytisine Natural products 0.000 description 1
- 229940027564 cytisine Drugs 0.000 description 1
- 230000003111 delayed Effects 0.000 description 1
- 230000003001 depressive Effects 0.000 description 1
- 239000002274 desiccant Substances 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 229960002069 diamorphine Drugs 0.000 description 1
- 229940042935 dichlorodifluoromethane Drugs 0.000 description 1
- 235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000002708 enhancing Effects 0.000 description 1
- 230000001856 erectile Effects 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000002496 gastric Effects 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-M glycolate Chemical compound OCC([O-])=O AEMRFAOFKBGASW-UHFFFAOYSA-M 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- MNWFXJYAOYHMED-UHFFFAOYSA-M heptanoate Chemical compound CCCCCCC([O-])=O MNWFXJYAOYHMED-UHFFFAOYSA-M 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000008240 homogeneous mixture Substances 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 230000002757 inflammatory Effects 0.000 description 1
- 200000000018 inflammatory disease Diseases 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-M iodide Chemical compound [I-] XMBWDFGMSWQBCA-UHFFFAOYSA-M 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000004500 isothiazol-4-yl group Chemical group S1N=CC(=C1)* 0.000 description 1
- 125000004501 isothiazol-5-yl group Chemical group S1N=CC=C1* 0.000 description 1
- 125000004498 isoxazol-4-yl group Chemical group O1N=CC(=C1)* 0.000 description 1
- 125000004499 isoxazol-5-yl group Chemical group O1N=CC=C1* 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 231100000863 loss of memory Toxicity 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 239000011776 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-L maleate(2-) Chemical compound [O-]C(=O)\C=C/C([O-])=O VZCYOOQTPOCHFL-UPHRSURJSA-L 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M methanoate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- 239000002324 mouth wash Substances 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-M naphthalene-2-sulfonate Chemical compound C1=CC=CC2=CC(S(=O)(=O)[O-])=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-M 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical compound C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 235000021096 natural sweeteners Nutrition 0.000 description 1
- 230000010807 negative regulation of binding Effects 0.000 description 1
- 230000000701 neuroleptic Effects 0.000 description 1
- 239000003176 neuroleptic agent Substances 0.000 description 1
- 230000000926 neurological Effects 0.000 description 1
- 230000000324 neuroprotective Effects 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 230000003000 nontoxic Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 210000000287 oocyte Anatomy 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 210000000056 organs Anatomy 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 125000004287 oxazol-2-yl group Chemical group [H]C1=C([H])N=C(*)O1 0.000 description 1
- 125000003145 oxazol-4-yl group Chemical group O1C=NC(=C1)* 0.000 description 1
- 125000004304 oxazol-5-yl group Chemical group O1C=NC=C1* 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000006201 parenteral dosage form Substances 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229940002612 prodrugs Drugs 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L propanedioate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- DNIAPMSPPWPWGF-UHFFFAOYSA-N propylene glycol Substances CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 1
- 125000004307 pyrazin-2-yl group Chemical group [H]C1=C([H])N=C(*)C([H])=N1 0.000 description 1
- 125000004944 pyrazin-3-yl group Chemical group [H]C1=C([H])N=C(*)C([H])=N1 0.000 description 1
- 125000002206 pyridazin-3-yl group Chemical group [H]C1=C([H])C([H])=C(*)N=N1 0.000 description 1
- 125000004940 pyridazin-4-yl group Chemical group N1=NC=C(C=C1)* 0.000 description 1
- GRFNBEZIAWKNCO-UHFFFAOYSA-N pyridin-3-ol Chemical compound OC1=CC=CN=C1 GRFNBEZIAWKNCO-UHFFFAOYSA-N 0.000 description 1
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 description 1
- 125000004528 pyrimidin-5-yl group Chemical group N1=CN=CC(=C1)* 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000000241 respiratory Effects 0.000 description 1
- 201000004700 rosacea Diseases 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- WSWCOQWTEOXDQX-UHFFFAOYSA-N sorbic acid Chemical compound CC=CC=CC(O)=O WSWCOQWTEOXDQX-UHFFFAOYSA-N 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-M stearate Chemical compound CCCCCCCCCCCCCCCCCC([O-])=O QIQXTHQIDYTFRH-UHFFFAOYSA-M 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 229940086735 succinate Drugs 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000002194 synthesizing Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 229960001367 tartaric acid Drugs 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000001225 therapeutic Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 125000000437 thiazol-2-yl group Chemical group [H]C1=C([H])N=C(*)S1 0.000 description 1
- 125000004495 thiazol-4-yl group Chemical group S1C=NC(=C1)* 0.000 description 1
- 125000004496 thiazol-5-yl group Chemical group S1C=NC=C1* 0.000 description 1
- YXFVVABEGXRONW-UHFFFAOYSA-N toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 1
- 230000000472 traumatic Effects 0.000 description 1
- 229940029284 trichlorofluoromethane Drugs 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- 201000004810 vascular dementia Diseases 0.000 description 1
- 239000002435 venom Substances 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 239000011345 viscous material Substances 0.000 description 1
- 230000002747 voluntary Effects 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
Abstract
The present invention discloses compounds represented by general formula (I) any of its enantiomers or any mixture thereof, or a pharmaceutically acceptable salt thereof;wherein m is 1, 2 or 3;n is 1, 2 or 3;R represents hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, aryl or aralkyl;and R1 represents a monocyclic 5 to 6 membered heterocyclic group which may be substituted one or more times with substituents selected from the group consisting of alkyl, cycloalkyl, cycloalkylalkyl, alkenyl, alkynyl, alkoxy, cycloalkoxy, methylenedioxy, halogen, CF3, OCF3, CN, amino, nitro, -COOR3, -CONR2R3, -NH-CO2R2, NHCO-R2, -OCO-NR2R3;wherein R2 and R3 independently represents hydrogen or alkyl;aryl optionally substituted one or more times with alkyl, cycloalkyl, cycloalkylalkyl alkenyl, alkynyl, alkoxy, cycloalkoxy, methylenedioxy, halogen, CF3, OCF3, CN, amino and nitro;-X-alkyl-Y-alkyl wherein X and Y independently represents O, S, NH, N-alkyl or Se;and alkyl is optionally substituted with alkoxy or thioalkoxy;-X-(alkyl)o-aryl- wherein o is 0 or 1 and X represents O, S, NH, N-alkyl or Se;optionally substituted one or more times with alkyl, cycloalkyl, cycloalkylalkyl alkenyl, alkynyl, alkoxy, cycloalkoxy, methylenedioxy, halogen, CF3, OCF3, CN, amino and nitro;-X-(alkyl)o-5- or 6-membered heterocyclic monocyclic group wherein o is 0 or 1 and X represents O, S, NH, N-alkyl or Se;optionally substituted one or more times with alkyl, cycloalkyl, cycloalkylalkyl alkenyl, alkynyl, alkoxy, cycloalkoxy, methylenedioxy, halogen, CF3, OCF3, CN, amino and nitro;a monocyclic 5 to 6 membered heterocyclic group optionally substituted one or more times with alkyl, cycloalkyl, cycloalkylalkyl, alkenyl, alkynyl, alkoxy, cycloalkoxy, methylenedioxy, halogen, CF3, OCF3, CN, amino and nitro;or R1 represents a bicyclic heterocyclic group, composed of a 5 to 6 membered monocyclic heterocyclic group fused to a benzene ring, and which may be substituted one or more times with substituents selected from the group consisting of alkyl, cycloalkyl, cycloalkylalkyl alkenyl, alkynyl, alkoxy, alkoxy-alkoxy, cycloalkoxy, methylenedioxy, halogen, CF3, OCF3, CN, amino, nitro, aryl optionally substituted one or more times with alkyl, cycloalkyl, cycloalkylalkyl alkenyl, alkynyl, alkoxy, cycloalkoxy, methylenedioxy, halogen, CF3, OCF3, CN, amino and nitro;and a monocyclic 5 to 6 membered heterocyclic group optionally substituted one or more times with alkyl, cycloalkyl, cycloalkylalkyl alkenyl, alkynyl, alkoxy, cycloalkoxy, methylenedioxy, halogen, CF3, OCF3, CN, amino and nitro. The compounds of the invention are useful as nicotinic ACh receptor ligands.
Description
NITROGENED RING ETHER DERIVATIVES AND THEIR USE AS NICOTINIC ACH RECEIVER MODULATORS
The present invention relates to novel pyridyl ether derivatives which are cholinergic ligands in nicotinic ACh receptors. The compounds of the invention are useful for the treatment of conditions or disorders or diseases involving the cholinergic system of the central nervous system, pain, inflammatory diseases, diseases caused by smooth muscle contractions and as auxiliaries to stop the excessive use of chemical substances.
BACKGROUND OF THE INVENTION
The endogenous cholinergic neurotransmitter, acetylcholine, exerts its biological effect through two types of cholinergic receptors: muscarinic ACh receptors and nicotinic ACh receptors. Since it has been well established that muscarinic ACh receptors dominate quantitatively over nicotinic ACh receptors in the brain area important for memory and cognition, the vast majority of research aimed at the development of agents for the treatment of disorders related to Memory has been focused towards the synthesis of modulators of the muscarinic ACh receptor. However, recently there has been an interest in the development of nicotinic ACh receptor modulators. Several diseases are associated with the degeneration of the cholinergic system, for example senile dementia of the Alzheimer type, vascular dementia and cognitive deterioration due to the organic disease of brain damage directly related to alcoholism. Indeed, various CNS disorders can be attributed to a cholinergic deficiency, a dopaminergic deficiency, an adrenergic deficiency or a serotonergic deficiency. Alzheimer's disease is characterized by a profound loss of memory and cognitive functions caused by a severe depression of cholinergic neurons, ie neurons that release acetylcholine. A reduction in the number of nicotinic ACh receptors with the progression of Alzheimer's disease has also been observed. It is believed that the death of cortical neurons with the progression of Alzheimer's disease is due to a lack of stimulation of nicotinic ACh receptors. It is predicted that treatment with modulators of nicotinic ACh receptor of patients with Alzheimer's disease will not only improve the patients' memory but also act to keep these neurons alive. At present, it seems that smoking protects individuals against neurodegeneration and the compounds that act on this receptor could probably have a generally neuroprotective effect. However, the degeneration of the cholinergic system is not limited to individuals suffering from diseases, for example Alzheimer's disease, but it has also been observed in adults and in healthy elderly rats. Therefore, it is suggested that the cholinergic system is involved and is partially responsible for the memory disturbances observed in animals and in elderly humans. Therefore, the nicotine receptor modulator can be useful in the treatment of Alzheimer's disease, memory loss, memory dysfunction, dementia associated with AIDS, senile dementia or neurodegenerative disorders. Parkinson's disease seems to involve the degeneration of dopaminergic neurons. It has been observed that a symptom of the disease is the loss of nicotinic receptors associated with dopaminergic neurons and that it possibly interferes with the dopamine release process. Since sustained administration of nicotine increases the number of receptors present, the administration of nicotine receptor modulators could improve the symptoms of Parkinson's disease. Another condition or disorders or disease associated with deficiencies in the dopaminergic system are: drug addiction, depression, obesity and narcolepsy. Tourette syndrome is a neuropsychiatric disorder that involves a range of neurological and behavioral symptoms. It is believed that neurotransmitter dysfunction is involved, although the pathophysiology is still unknown and whether nicotine will be beneficial in the treatment of the disease (Devor et al., The Lancet, vol.8670 p.1046, 1989). Schizophrenia is a severe psychiatric illness. Neuroleptic compounds have been used in the treatment of the disease, and it is believed that the effect of the compounds is due to the interaction of these in the dopaminergic system. It is proposed that nicotine is effective in the treatment of schizophrenia (Adler et al., Biol Psychiatry, Vol. 32, pp. 607-616, 1992). It has been reported that nicotine has an effect on the release of the neurotransmitter in various systems. It has been reported that neurons release acetylcholine and dopamine after administration of nicotine (J. Neurochem, vol 43, 1593-1598, 1984) as well as the release of norepinephrine by Hall et. to the. (Biochem Pharmacol., Vol.21, 1829-1838, 1972). The release of serotonin by Hery et. al (Arch. Int. Farmacodyn, Ther. vol 296. pp. 91-97, 1977). The release of glutamate by Toth et. to the. (Neurochem, Res. Vol.17, p.265-271, 1992). It is believed that the serotonin system and dysfunction of the serotonergic system are involved in diseases or conditions or disorders such as: anxiety, depression, appetite disorders, obsessive-compulsive disorder, panic disorders, excessive use of chemical substances, alcoholism, pain, lack of memory and anxiety, pseudodementia, Ganser syndrome, migraine pain, bulimia, obesity, pre-menstrual syndrome or late luteal phase syndrome, excessive use of tobacco, post-traumatic syndrome, social phobia, chronic fatigue syndrome, premature ejaculation, difficulty of erection, anorexia nervosa, sleep disorders, autism, mutism or trichotillomania.
Nicotine improves the performance of concentration and tasks. Therefore, compounds that exhibit nicotine receptor modulating properties will likely be compounds useful in the treatment of learning deficiency, cognitive deficiency, attention deficiency, attention deficit hyperactivity disorder and dyslexia. It is recognized that the use of tobacco and especially cigarette smoking is a serious health problem. However, the nicotinic withdrawal symptoms associated with quitting smoking make it difficult to break this habit. Withdrawal symptoms include anger, anxiety, difficulty concentrating, restlessness, decreased heart rate and increased appetite and weight gain. Nicotine itself has been shown to ease withdrawal symptoms. Stopping the use of substances that cause addiction, for example opiates, benzodiazepines, ethanol, tobacco or nicotine, is in general a traumatic experience characterized by anxiety and frustration. It has been found that nicotine is effective in reducing irritability, anger, frustration and feelings of tension without causing a general response of depression, drowsiness or sedation and it is likely that compounds that have the same characteristics of nicotine have the same effects. Normally, mild to moderate pain can be treated with NSAIDs (non-steroidal anti-inflammatory drugs) although it is preferred to be used in opioids to treat moderate to severe pain. Opioids have some well-known side effects, including chemical dependence and potential for overuse as well as a depressive effect on the respiratory and gastrointestinal system. There is therefore a strong need for analgesic compounds that do not have these side effects and that can relieve mild, moderate and severe pain of an acute, chronic or recurrent nature as well as migraine pain and postoperative pain, extremity pain ghost. Epibatidine, a compound isolated from the skin of a poison frog, is a very potent analgesic with an approximate potency of 500 times that of morphine. The analgesic effect is not affected by naloxone, which is an indication of very little affinity towards the opiate receptors. Epibatidine is a nicotinic cholinergic receptor agonist and it is therefore very likely that compounds possessing this receptor modulator character also have a strong analgesic response. The compounds of the invention have proven to be useful for modulating smooth muscle contractions and therefore could be used in the treatment or prevention of condition or disorders or diseases inherent in smooth muscle contractions such as convulsive disorders, angina pectoris , premature birth, seizures, diarrhea, asthma, epilepsy, tardive dyskinesia and hyperkinesia. Furthermore, it is well known that nicotine has an effect on appetite and it is predicted that modulators of the nicotinic ACh receptor may be useful as appetite suppressants in the treatment of obesity and eating disorders. Cholinergic receptors play an important role in the functioning of muscles, organs and generally in the central nervous system. There are also complex interactions between cholinergic receptors and the function of the receptors of other neurotransmitters such as dopamine, serotonin and noradrenaline. It is likely that nicotine receptor modulating compounds may be effective in preventing or treating conditions or disorders or diseases such as: inflammation, inflammatory skin conditions, Chron's disease, inflammatory bowel disease, ulcerative colitis, diarrhea, neurodegeneration, peripheral neuropathy , lateral amyotrophic sclerosis, nociception, endocrine disorders, thyrotoxicosis, pheochromocytoma, hypertension, arrhythmias, mania, manic depression, Huntington's disease, delayed sleep cycle effect (jetlag). The compounds of the present invention are modulators of the nicotine receptor, and have the potential to exhibit nicotinic pharmacology, preferably without the side effects associated with nicotine itself. Additionally, compounds are expected to have the potential to act as neurotransmitter secretion enhancers and to suppress symptoms associated with low neurotransmitter activity.
OBJECTIVES OF THE INVENTION
It is an object of the present invention to provide novel pyridyl ether derivatives which are useful for the treatment of a range of diseases and disorders characterized by decreased cholinergic function or which respond to the activity of nicotinic ACh receptor agonists. Another objective of the present invention is to provide novel pharmaceutical compositions containing these compounds, as well as methods for the preparation thereof and methods for the treatment thereof. Hereinafter, other objects will become apparent to a person skilled in the art.
BRIEF DESCRIPTION OF THE INVENTION
The invention then, among other things, comprises the following, alone or in combination: A compound having the formula
(I) any of its enantiomers or any mixture thereof, or a pharmaceutically acceptable salt thereof; wherein m is 1, 2 or 3; n is 1, 2 or 3; R represents hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, aryl or aralkyl; and R1 represents a 5-6 membered monocyclic heterocyclic group which may be substituted one or more times with substituents that are selected from the group consisting of alkyl, cycloalkyl, cycloalkylalkyl, alkenyl, alkynyl, alkoxy, cycloalkoxy, methylenedioxy, halogen, CF3 , OCF3, CN, amino, nitro, -COOR3, -CONR2R3, -NH-CO2R2, NHCO-R2, -OCO-NR2R3; wherein R2 and R3 independently represent hydrogen or alkyl; aryl optionally substituted one or more times with alkyl, cycloalkyl, cycloalkylalkylalkenyl, alkynyl, alkoxy, cycloalkoxy, methylenedioxy, halogen, CF3, OCF3, CN, amino and nitro; X-alkyl-Y-alkyl wherein X and Y independently represent O, S, NH, N-alkyl or Se; and alkyl is optionally substituted with alkoxy or thioalkoxy; -X- (alkyl) 0-aryl- wherein o is 0 or 1 and X represents O, S, NH, N-alkyl or Se; optionally substituted one or more times with alkyl, cycloalkyl, cycloalkylalkylalkenyl, alkynyl, alkoxy, cycloalkoxy, methylenedioxy, halogen, CF3, OCF3, CN, amino and nitro; monocyclic heterocyclic group -X- (alkyl) 0-5- or 6-membered wherein o is 0 or 1 and X represents O, S, NH, N-alkyl or Se; optionally substituted one or more times with alkyl, cycloalkyl, cycloalkylalkylalkenyl, alkynyl, alkoxy, cycloalkoxy, methylenedioxy, halogen, CF3, OCF3, CN, amino and nitro; a monocyclic 5- to 6-membered heterocyclic group optionally substituted one or more times with alkyl, cycloalkyl, cycloalkylalkyl, alkenyl, alkynyl, alkoxy, cycloalkoxy, methylenedioxy, halogen, CF3, OCF3, CN, amino and nitro; or R1 represents a bicyclic heterocyclic group, composed of a 5- to 6-membered monocyclic heterocyclic group fused to a benzene ring, and which may be substituted one or more times with substituents that are selected from the group consisting of alkyl, cycloalkyl, cycloalkylalkylalkenyl, alkynyl, alkoxy, alkoxy-alkoxy, cycloalkoxy, methylenedioxy, halogen, CF3, OCF3, CN, amino, nitro, aryl optionally substituted one or more times with alkyl, cycloalkyl, cycloalkylalkylalkenyl, alkynyl, alkoxy, cycloalkoxy, methylenedioxy, halogen, CF3, OCF3, CN, amino and nitro; and a 5- to 6-membered monocyclic heterocyclic group optionally substituted one or more times with alkyl, cycloalkyl, cycloalkylalkylalkenyl, alkynyl, alkoxy, cycloalkoxy, methylenedioxy, halogen, CF3, OCF3CN, amino and nitro;
Compounds as indicated above may contain isotopes of one or more of the atoms present. A pharmaceutical composition, comprising a therapeutically effective amount of a compound of the above or a pharmaceutically acceptable addition salt thereof, together with at least one pharmaceutically acceptable carrier or diluent. The use of a compound as above for the manufacture of a medicament for the treatment or prevention of a condition or disorder or disease of a live animal, including a human, whose condition or disorder or disease responds to the activity of nicotinic ACh receptor modulators. A method for treating a disease in a living animal, including a human, whose disease responds to the activity of the nicotinic ACh receptor modulators, comprising the step of administering to such a living animal, including a human, in need thereof, a Therapeutically effective amount of a compound as the above.
DETAILED DESCRIPTION OF THE INVENTION
In a preferred embodiment of the invention, the chemical compound of the formula (I) an acetidine, pyrrolidine, piperidine or a homopiperidine is the group bridging R and R1.
In another preferred embodiment of the invention R is hydrogen or C 1-4 alkyl; and R1 represents a pyridyl or a substituted pyridyl. In a more preferred embodiment, R1 is 3-pyridyl, 5-chloro-3-pyridyl, 2-chloro-3-pyridyl. In another preferred embodiment the chemical compound of the invention is a compound of the general formula (I) said compound being: (± 1-Methyl-3-oxy- (3-pyridyl) -pyrrolidine; (± 1-Methyl) -3-oxy (3-pyridyl) -azetidine; (± 1-Methyl-3-oxy (3-pyridyl) -piperidine; (±., 1-Methyl-3-oxy) (5-chloro-3-) pyridyl) -pyrrolidine; (±.? -1-Methyl-3-oxy (5-chloro-3-pyridyl) -piperidine; (±? -1- ethyl-3-oxy (2-chloro-3-) pyridyl) -piperidine; (±: -1-Methyl-4-oxy (3-pyridyl) -homopiperidine; (±: -1-Met.l-4-oxi (5-chloro-3-p Ridyl) -homopiperidine; (±:? -3-Oxy- (3-pyridyl) -pyrrolidine; (± 3-Oxy- (3-pyridyl) -azetidine; ? -3-Oxy- (3-pyridyl) -piperidine; (± - (5-chloro-3-pyridyl) -3-oxi-pyrrolidine; (±: - (5-chloro-3-pyr Dil) -3-oxy-piperidine; (±? - (2-chloro-3-pyridyl) -3-oxi-piperidine; (± 4-Oxi- (3-pyridyl) -homopiperi; d, or (+) - (5-chloro-3-pyridyl) -4-oxy-homopiperidine, any of its enantiomers or any of mixtures thereof, or a pharmaceutically salt acceptable of it.
Pharmaceutically acceptable addition salts The chemical compound of the invention can be provided in any suitable form for the proposed administration. Suitable forms include pharmaceutically acceptable salts (i.e., physiologically), and pre- or prodrug forms of the chemical compound of the invention. Examples of pharmaceutically acceptable addition salts include, without limitation, non-toxic organic and inorganic acid addition salts, such as acetic acid acetate acetate, aconitic acid derivative, ascorbic acid ascorbic acid derivative, benzene sulphonate benzene sulphonic acid derivative, benzoate derived from benzoic acid, cinnamic acid derived from cinnamic acid, citrate derived from citric acid, embonic acid derived from embonic acid, enanthate derived from enanthic acid, formate derived from formic acid, derived fumarate of fumaric acid, glutamate derived from glutamic acid, glycollate derived from glycolic acid, hydrochloride derived from hydrochloric acid, bromohydrate derived from hydrobromic acid, lactate derived from lactic acid, maleate derived from maleic acid, malonate derived from acid malonic acid, mandelic acid derived from mandelic acid, methanesulfon ato derived from methanesulfonic acid, naphthalene-2-sulfonate derived from naphthalene-2-sulfonic acid, nitrate derived from nitric acid, perchlorate derived from perchloric acid, phosphate derived from phosphoric acid, phthalate derived from italic acid, salicylate derived from salicylic acid, sorbate derived from sorbic acid, stearate derived from stearic acid, succinate derived from succinic acid, sulphate derived from sulfuric acid, tartrate derived from tartaric acid, toluene-p-sulfonate derived from acid p-toluene sulphonic, and the like. Said salts can be formed by methods known and described in the art. Other acids, such as oxalic acid, which can not be considered pharmaceutically acceptable, may be useful in the preparation of salts useful as intermediates in obtaining a chemical compound of the invention and its pharmaceutically acceptable acid addition salt. The metal salts of a chemical compound of the invention include alkali metal salts, such as the sodium salt of a chemical compound of the invention which contains a carboxy group. The chemical compound of the invention can be provided in solvated or unsolvated form together with pharmaceutically acceptable solvents, such as water, ethanol and the like. In general, solvated forms are considered equivalent to dissolved forms for the purpose of this invention.
Spherical isomers The chemical compounds of the present invention can exist in (+) and (-) forms as well as in racemic forms. The racemates of these isomers and the individual isomers themselves are within the scope of the present invention. Racemic forms can be resolved at optical antipodes through known methods and techniques. One way to separate the diastereomeric salts is by the use of an optically active acid, and the optically active amine compound is released by treatment with a base. Another method for resolving racemates in optical antipodes is based on chromatography in an optical active matrix. The racemic compounds of the present invention can therefore be resolved in their optical antipodes, for example, through fractional crystallization of d- or I- salts (tartrates, mandelics or camphor sulfonate), for example. The chemical compounds of the present invention can also be resolved by the formation of diastereomeric amides by reacting the chemical compounds of the present invention with an optically active activated carboxylic acid, such as that which is derived from (+) or (-) phenylalanine. , (+) or (-) phenylglycine, (+) or (-) cananic acid or by the formation of diastereomeric carbamates through the reaction of the chemical compound of the present invention with an optically active chloroformate or the like.
Additional methods for resolution of optical isomers are known in the art. Such methods include those described by Jaques J, Collet A, & Wilen S in "Enantiomers, Racemates, and Resolutions". John Wiley and Sons, New York (1981). In addition, some of the chemical compounds of the invention contain double bonds and therefore can exist in two forms, cis- and trans- forms (Z- and E- form), depending on the placement of the substituents around the double bond. C = C-. A chemical compound of the present invention can therefore be cis- or trans- (form Z and E) or it can be a mixture thereof.
Definition of substitutents Halogen is fluoride, chloride, bromide or iodide. Alkyl means a straight chain or branched chain of one to eight carbon atoms, including but not limited to methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, pentyl and hexyl; cycloalkyl means cyclic alkyl of three to seven carbon atoms, including but not limited to cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl; "alkenyl" means a group of two to six carbon atoms, including at least one double bond, for example, but not limited to ethenyl, 1, 2- or 2,3-propenyl, 1, 2- or 2,3- or 3 , 4-butenyl.
alkynyl means a group of two to six carbon atoms, including at least one triple bond, for example without being limited to ethynyl, 1, 2- or 2,3-propynyl, 1, 2- or 2,3- or 3,4 -butinyl. Cycloalkylalkyl means cycloalkyl as described and alkyl as already described, which means for example cyclopropylmethyl. Alkoxy is O-alkyl, wherein alkyl is as defined above. Cycloalkoxy is O-cycloalkyl, wherein cycloalkyl is as defined above. Alkenoxy is O-alkenyl, wherein alkenyl is as described above. Alkynoxy is O-alkynyl, wherein alkynyl is as described above; Thioalkoxy is S-alkyl, wherein alkyl is as defined above. Amino is NH2 or NH-alkyl or N- (alkyl) 2, wherein alkyl is as defined above. A heterocyclic group of 5 to 6 monocyclic elements, for example, oxazol-2-yl, oxazol-4-yl, oxazol-5-yl, soxazol-3-yl, isoxazol-4-yl, isoxazol-5-yl , thiazol-2-yl, thiazol-4-yl, thiazol-5-yl, siathiazol-3-yl, isothiazol-4-yl, isothiazol-5-yl, 1,4-oxadiazol-3-yl, 1, 2,4-oxadiazol-5-yl, 1,4-thiadiazol-3-yl, 1,4-thiadiazol-5-yl, 1, 2,5-oxadiazol-3-yl, 1, 2,5-oxadiazol-4-yl, 1, 2,5-thiadiazol-3-yl, 1, 2,5-thiazol-4-yl, 1-imidazoloyl, 2-imidazolyl, 4-imidazolyl, 1-pyrrolyl, 2-pyrrolyl, 3-pyrrolyl, 2-furanyl, 3-furanyl, 2-thienyl, 3-thienyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, pyrimidinyl, 4-pyrimidinyl, 5-pyrimidinyl, 3-pyridazinyl, 4-pyridazinyl, 2-pyrazinyl and 3-pyrazinyl and 1-pyrazolyl, 3-pyrazolyl and 4-pyrazolyl. A bicyclic heterocyclic group consisting of a monocyclic heterocyclic group of 5 to 6 elements and a fused benzene ring means a heterocyclic group of 5 to 6 monocyclic elements as described, which is fused to a benzene ring, which includes, for example, -, 3-, 4-, 5-, 6-, 7-benzofu ramie, 1-, 2-, 4-, 5-benzimidazolyl, 2-, 3-, 4-, 5-, 6-, 7-indolyl , 2-, 3-, 4-, 5-, 6-, 7-, 8-quinoliniio and 1-, 3-, 4-, 5-, 6-, 7-, 8-isoquinolinilo. Aryl is an aromatic hydrocarbon, such as phenyl and naphthyl. Aralkyl means alkyl as described above and aryl as described, meaning for example benzyl, phenethyl. Isotopes means one or more atoms in the compound substituted with an isotope of atoms as they occur in nature and includes, but is not limited to, deuterium, tritium, 13 ^ C, 14 C-, 131? I, 125. 123. 18 5F; In addition, the compounds of this invention can exist in unsolvated forms, as well as in solvated forms, with pharmaceutically acceptable solvents, such as water, ethanol and the like. In general, solvated forms are considered equivalent to unsolvated forms for the purposes of this invention. Those skilled in the art will appreciate that the compounds of the present invention may contain several chiral centers and that said compounds exist in the form of isomers (ie, enantiomers). The invention includes said isomers and any mixture thereof including racemic mixtures. The racemic forms can be resolved into optical antipodes by known methods, for example, by separating diastereomeric salts thereof with an optically active acid, and by releasing the optically active amine compound by treatment with a base. Another method for resolving racemates in the optical antipodes is based on chromatography on an optically active matrix. The racemic compounds of the present invention can therefore be resolved in their optical antipodes, for example, by fractional crystallization of d- or I- salts (tartrates, mandelates, or camphor sulfonates). The compounds of the present invention can also be resolved by the formation of diastereomeric amides through the reaction of the compounds of the present invention with an optically active activated carboxylic acid, such as that which is derived from (+) or (-) phenylalanine, (+) or (-) phenylglycine, (+) or (-) cananic acid or by the formation of diastereomeric carbamates through the reaction of the compounds of the present invention with an optically active chloroformate or the like. Additional methods for resolving known optical isomers may be employed, and will be apparent to those skilled in the art. These methods include those addressed by J. Jaques, A. Collet and S.
Wilen in "Enantiomers, Racemates, and Resolutions", John Wiley and Sons, New York (1981). The optically active compounds can also be prepared from optically active starting materials. The compounds of the invention can be prepared by any conventional method useful for the preparation of analogous compounds and as described in the examples below. The starting materials for the processes described in the present patent application are known or can be prepared by known methods from commercially available materials. A compound of the invention can be converted to another compound of the invention using conventional methods. The products of the reactions described herein are isolated by conventional means, such as extraction, crystallization, distillation, chromatography and the like.
Biology Nicotinic ACh receptors in the brain are pentameric structures composed of units different from those found in skeletal muscle. The existence of eight subunits a (a2-a9) and three subunits ß (ß2-ß4) in the mammalian brain has been described.
The predominant subtype with a high affinity for nicotine is composed of three a4 subunits and two β2 subunits. The affinity of the compounds of the invention for nicotinic ACh receptors has been investigated in three tests in terms of in vitro inhibition of 3 H-epibatidine binding, binding to 3 H-to-bungarotoxin and binding to 3 H-cytisine as described later:
In vitro inhibition of 3H-cytisine binding The predominant subtype with high affinity for nicotine is composed of a4 and β2 subunits- The nAChR of this latter type can be selectively labeled by the nicotine modulator 3H-cytisine.
Tissue preparation The preparations were made at 0-4 ° C, unless otherwise indicated. The cerebral cortexes from male Wistar rats (150-250g) were homogenized for 20 seconds in 15 ml of Tris, HCl (50 mm, pH 7.4) containing 120 mM NaCl, 5 mM KCI, 1 mM MgCl2 and 2.5 mM of CaC using an Ultra-Turrax homogenizer. The homogenized material was centrifuged at 27,000 x g for 10 minutes. The supernatant was discarded and the pellet was resuspended in fresh buffer and centrifuged a second time. The final pellet was resuspended in fresh buffer solution (35 μg per gram of original tissue) and used for binding tests.
Test Aliquots of 500 μl of the homogenate were added to 25 μl of the test solution and 25 μl of 3 H-cytisine (final concentration 1 mM), mixed and incubated for 90 minutes at 2 ° C. The non-specific binding was determined using (-) - nicotine (final concentration 100 μM). After incubation, 5 ml of ice-cold buffer solution was added to the samples and poured directly into Whatman GF / C glass fiber filters under suction and immediately washed with 2 x 5 ml of ice-cold buffer solution. The amount of radioactivity in the filters was determined by conventional liquid scintillation technique. The specific binding is the total union minus the non-specific binding.
In vitro inhibition of Ha-bunqarotoxin binding in rat brain A-bungatoroxin is a peptide isolated from the venom of the viper Bungarus multicinctus of the Elapidae family (Mebs et al., Biochem. Biophys. Res. Commun., 44 (3 ), 711 (1971)), and has high affinity for neuronal and neuromuscular nicotinic receptors, where it acts as a potent antagonist. 3 H-a-bungarotoxin binds to an individual site in the rat brain with a unique distribution pattern in the rat brain (Clarke et al., J. Neurosa, 5, 1307-1315 (1985)). The 3H-a-bungarotoxin marks the nAChR formed by the form of the a7 subunit found in the brain and the isoform ai in the neuromuscular junction (Changeaux, Fidia Res. Found. Neurosci. Found, Lect. 4, 21-168 ( 1990) Functionally, the a7 homo-oligomer expressed in the oocytes has a greater calcium permeability than that of the neuromuscular receptors and, in some cases, greater than the NMDA channels (Seguela et al., J. Neurosci., 13, 596 -604 (1993).
Tissue preparation The preparations were made at 0-4 ° C, unless otherwise indicated. The cerebral cortexes from male Wistar rats (150-250 g) were homogenized for 10 seconds in 15 ml of 20 mM Hepes buffer solution containing 118 mM NaCl, 4.8 mM KCI, 1.2 mM MgSO4 and 2.5 mM CaCl2 ( pH 7.5) using an Ultra-Turrax homogenizer. The tissue suspension was centrifuged at 27,000 x g for 10 minutes. The supernatant was discarded and the pellet was washed twice by centrifugation at 27,000 xg for 10 minutes in 20 ml of fresh buffer, and the final pellet was resuspended in fresh buffer containing 0.01% BSA (35 ml per cell). gram of original tissue) and was used for the binding tests.
Test Aliquots of 500 μl of the homogenized material were added to 25 μl of the test solution and 25 μl of 3 H -bungarotoxin (final concentration 2 nM), mixed and incubated for 2 hours at 37 ° C. The non-specific binding was determined using (-) - nicotine (final concentration 1 mM). After incubation, 5 ml of ice cold Hepes buffer containing 0.05% PEI was added to the samples and poured directly into Whatman GF / C glass fiber filters (previously soaked in 0.1% PEI for at least 6 hours) under suction and immediately washed with 2 x 5 ml of ice buffer. The amount of radioactivity in the filters was determined by conventional liquid scintillation technique. The specific binding is the total union minus the non-specific binding.
In vitro inhibition of binding to 3H-epibatidine Epibatidine is an alkaloid that was first isolated from the skin of the Ecuadorean frog Epipedobates tricolor and found to have a high affinity towards neuronal nicotinic receptors, where it acts as a potent agonist. . 3 H-epibatidine binds to two sites in the rat brain, both of which have pharmacological profiles consistent with neuronal nicotinic receptors and a similar regional distribution in the brain (Hougling et al., Mol.Pharmacol., 48, 280- 287 (1995)). The high affinity binding site for 3H-epibatidine is surely the binding to the a4ß2 subtype of nicotinic receptors. The identity of the low affinity site is still unknown; it represents a second nicotinic receptor or a second site in the same receptor. The inability of a-bungarotoxin to compete for 3 H-epibatidine binding sites indicates that none of the sites measured represents the nicotinic receptor composed of a7 subunits.
Tissue preparation The preparations were made at 0-4 ° C, unless otherwise indicated. The posterior brain (+ cerebellum) from a male Wistar rat (150-250 g) was homogenized for 10-20 seconds in 20 ml of Tris, HCl (50 mM, pH 7.4) using an Ultra-Turrax homogenizer. The tissue suspension was centrifuged at 27,000 x g for 10 minutes. The supernatant was discarded and the pellet was washed three times by centrifugation at 27,000 xg for 10 minutes in 20 ml of fresh buffer, and the final pellet was resuspended in buffer solution (400 ml per gram of original tissue) and used for the binding tests.
Test Aliquots of 2.0 ml of homogenized material were added to 0.1 ml of the test solution and 0.1 ml of 3 H-epibatidine (final concentration 0.3 nM) was mixed and incubated for 60 minutes at room temperature. The non-specific binding was determined using (-) - nicotine (final concentration 30 μM). After incubation the mixtures were poured directly onto Whatman GF / C glass fiber filters (previously soaked in 0.1% PEI for at least 20 minutes) under suction and immediately washed with 2 x 5 ml of ice cold buffer. The amount of radioactivity in the filters was determined by conventional liquid scintillation technique. The specific binding is the total union minus the non-specific binding.
Compound 3 ?: 3H- *? Üx- cytisine epibatidine bungarotoxin Cl50 (μM) IC50 (μM) Cl50 (μM)
1-Methyl-3-oxy- (3-pyridyl) -pyrrolidine (1a) 0.10 0.70 16.0
1 - . 1 -Met-1-3-oxy- (3-pyridyl) -pyridine (3a) 0.19 0.72 19.0
Salt of 4-oxy- (3-pyridyl) -0.06 0.30 20.0 homopiperidinfumárico (7b) 3-Oxy- (3-pyridyl) -pyrrolidine (1 b) 0.07 0.41 > 30
The compounds of the present invention show a high degree of binding affinity, as well as selectivity for one or more of the receptor subtypes. Therefore, they have been shown to be useful as modulators of selective receptors of the nicotine receptor subtypes.
Pharmaceutical Compositions Although it is possible that, for use in therapy, a compound of the invention may be administered as the crude chemical substance, it is preferable to present the active ingredient as a pharmaceutical formulation. Therefore, the invention further provides pharmaceutical formulations comprising a compound of the invention or a pharmaceutically acceptable salt or derivative thereof together with one or more pharmaceutically acceptable carriers therefor and, optionally, other therapeutic and / or prophylactic ingredients. The vehicle or vehicles must be "acceptable" in the sense of being compatible with the other ingredients of the formulation and not damaging the recipient thereof. Pharmaceutical formulations include those suitable for oral, rectal, nasal, topical (including buccal and sublingual), vaginal or parenteral (including intramuscular, subcutaneous and intravenous) administration or in a form suitable for administration by inhalation or insufflation. The compounds of the invention, together with a conventional adjuvant, vehicle or diluent, can therefore be placed in the form of pharmaceutical compositions and unit doses thereof and in such a form that they can be used as solids, such as tablets or filled capsules, liquids such as solutions, suspensions, emulsions, elixirs or capsules filled therewith, all for oral use, in the form of suppositories for rectal administration; or in the form of sterile injectable solutions for parenteral use (including subcutaneous). Said pharmaceutical compositions and dosage unit forms thereof may comprise conventional ingredients in conventional proportions, with or without additional active compounds or principles, and said unit dosage forms may contain any effective and adequate amount of the active ingredient provided at the dose scale. intended daily that will be employed. Formulations containing ten (10) milligrams of active ingredient or, more broadly, 0.1 to one hundred (100) milligrams, per tablet are also representative and suitable unit dose forms. The compounds of the present invention can be administered in a wide variety of oral and parenteral dosage forms. It will be apparent to those skilled in the art that the following dosage forms may comprise, as the active component, either a compound of the invention or a pharmaceutically acceptable salt of a compound of the invention. To prepare pharmaceutical compositions from the compounds of the present invention, pharmaceutically acceptable carriers can be solid or liquid. Solid form preparations include powders, tablets, pills, capsules, seals, suppositories and dispersible granules. A solid carrier may be one or more substances which may also act as diluents, flavoring agents, solubilizers, lubricants, suspending agents, binders, preservatives, tablet disintegrating agents or an encapsulating material. In powders, the carrier is a finely divided solid that is in a mixture with the finely divided active component. In tablets, the active component is mixed with the vehicle having the necessary binding capacity in suitable proportions and is compacted in the desired shape and size. The powders and tablets preferably contain from 5 or 10 to about 70% of the active compound. The right vehicles are magnesium carbonate, magnesium stearate, talc, sugar, lactose, pectin, dextrin, starch, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose, a low melting wax, cocoa butter and the like. The term "preparation" is intended to include the formulation of the active compound with encapsulating material as a vehicle that provides a capsule in which the active component, with or without vehicles, is surrounded by a vehicle, which is therefore associated with the same. Similarly, sacks and pills are included. Tablets, powders, capsules, pills, sacks and pills can be used as solid forms suitable for oral administration. To prepare suppositories, a low melting point wax, such as a mixture of fatty acid glycerides or cocoa butter, is first melted, and the active component is dispersed homogeneously therein, by stirring. The molten homogeneous mixture is then poured into molds of suitable size, allowed to cool and subsequently solidified. Formulations suitable for vaginal administration may be presented as pessaries, tampons, creams, gels, pastes, foams or sprays which contain in addition to the active ingredient such vehicles which are known to be suitable in the art. Liquid form preparations include solutions, suspensions and emulsions, for example, solutions with water or water-propylene glycol. For example, liquid preparations in parenteral injection can be formulated as solutions in aqueous polyethylene glycol solution. The compounds according to the present invention can therefore be formulated for parenteral administration (for example, injection, for example bolus injection or continuous infusion) and can be presented in the form of unit doses in ampoules, prefilled syringes, low volume infusion or in multiple dose containers with an added preservative. The compositions may take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles and may contain formulatory agents, such as suspending, stabilizing and / or dispersing agents. Alternatively, the active ingredient may be in powder form, obtained by aseptic isolation of sterile solid or by solution lyophilization, for constitution with a suitable vehicle, eg, pyrogen-free sterilized water, before use. Aqueous solutions suitable for oral use can be prepared by dissolving the active component in water and adding suitable colorants, flavors, stabilizing agents and thickeners, as desired. Aqueous suspensions suitable for oral use can be made by dispersing the finely divided active component in water with viscous material, such as natural or synthetic gums, resins, methylcellulose, sodium carboxymethylcellulose or other known suspending agents. Also included are solid form preparations which are intended to be converted, just before use, into liquid form preparations for oral administration. Said liquid forms include solutions, suspensions and emulsions. These preparations may contain, in addition to the active component, colorants, flavors, stabilizers, pH regulators, artificial and natural sweeteners, dispersants, thickeners, solubilizing agents and the like. For topical administration to the epidermis, the compounds according to the invention can be formulated as ointments, creams or lotions or as a transdermal patch. The ointments and creams can for example be formulated with an aqueous or oily base with the addition of suitable thickening and / or gelling agents. The lotions may be formulated with an aqueous or oily base and will generally also contain one or more emulsifying agents, stabilizing agents, dispersing agents, suspending agents, thickening agents or coloring agents. Formulations suitable for topical administration in the mouth include troches comprising active agents in a flavoring base, usually sucrose and acacia or tragacanth; the tablets comprising the active ingredient in an inert base, such as gelatin and glycerin or sucrose and acacia; and mouth rinses comprising the active ingredient in a suitable liquid vehicle.
The solutions or suspensions are applied directly to the nasal cavity through conventional means, for example with a dropper, pipette or sprinkler. The formulations can be provided in simple form or in multiple doses. In the latter case of a dropper or pipette, this can be achieved if the patient administers a predetermined appropriate volume of the solution or suspension. In the case of a sprinkler, it can be achieved, for example, by means of an atomizing spray pump with measurement. Administration to the respiratory tract can also be achieved by means of an aerosol formulation in which the active ingredient is supplied in a pressurized package with a suitable impeller such as chlorofluorocarbon (CFC) for example dichlorodifluoromethane, trichlorofluoromethane, or dichlorotetrafluoroethane, carbon dioxide, or another suitable gas. The aerosol may also conveniently contain a surfactant such as lecithin. The dosage of medication can be controlled by the provision of a metering valve. Alternatively, the active ingredients may be provided in the form of a dry powder, for example a powder mixture of the compound in a suitable powder base such as lactose, starch, starch derivatives such as hydroxypropylmethylcellulose and polyvinylpyrrolidone (PVP). Conveniently the powder vehicle will form a gel in the nasal cavity. The powder composition can be presented in unit dosage form for example in capsules or cartridges of, for example, gelatin, or bubble packings from which the powder can be administered by means of an inhaler. In formulations designed for administration to the respiratory tract, including intranasal formulations, the compound will generally have a small particle size for example of the order of 5 microns or less. Said particle size can be obtained by means known in the art, for example by micronization. When desired, formulations adapted to give sustained release of the active ingredient can be used. The pharmaceutical preparations are preferably in unit dosage forms. In such form, the preparation is subdivided into unit doses containing suitable quantities of the active component. The unit dosage form may be a packaged preparation, the package containing small amounts of preparation, such as packed tablets, capsules, and powders in vials or ampoules. In addition, the unit dosage form can be a capsule, tablet, wafer, or dragee itself, or it can be the appropriate number of any of those in packaged form. Tablets or capsules for oral administration and liquids for intravenous administration are the preferred compositions.
Method of treatment The compounds of the present invention are valuable modulators of the nicotinic ACh receptor and therefore useful for the treatment of a range of diseases involving cholinergic dysfunction as well as a range of disorders that respond to the activity of receptor modulators. Nicotinic ACh. The compounds can be used in the treatment, prevention, prophylaxis or improvement of a disease, disorder or condition of the central nervous system such as for example: neurodegenerative disorders, memory or cognitive dysfunction, Alzheimer's disease, Parkinson's disease, Huntington, lateral amyotrophic sclerosis, Gilles de la Tourette syndrome, attention deficit hyperactivity disorder, anxiety, depression, mania, manic depression, schizophrenia, obsessive-compulsive disorders, eating disorders such as anorexia nervosa, bulimia and obesity, narcolepsy, nociception, memory loss, memory dysfunction, dementia associated with AIDS, senile dementia, peripheral neuropathy, learning deficiency, cognitive deficiency, attention deficiency, autism, dyslexia, tardive dyskinesia, hyperkinesia, epilepsy, bulimia, post-traumatic syndrome, social phobia, chronic fatigue syndrome, sleep disorders, pseudodementia, Ganser syndrome, pre-menstrual syndrome, late luteal phase syndrome, chronic fatigue syndrome, premature ejaculation, Erectile difficulty, mutism and trichotillomania. The compounds of this invention can also be used in the treatment of inflammatory conditions such as for example: inflammatory conditions of the skin such as acne and rosacea, Chron's disease, inflammatory bowel disease, ulcerative colitis, diarrhea.
In addition, the compounds of the invention can be used in the treatment of diseases associated with smooth muscle contractions such as for example: seizure disorders, angina pectoris, premature labor, seizures, diarrhea, asthma, epilepsy, tardive dyskinesia, hyperkinesia. The compounds of this invention may also be useful in the treatment of pain such as, for example, chronic, acute and recurrent pain, postoperative pain, migraine pain or phantom limb pain. The compounds of the present invention can be used to help stop the excessive use of chemical substances such as for example quitting smoking, as well as stop using other products containing nicotine, stop using opioids such as heroin, cocaine and morphine and to stop using benzodiazepines or alcohol. In the context of the present invention "treatment" means both treatment and prevention, prophylaxis and improvement of the symptoms of abstinence and abstinence as well as the resulting treatment in a voluntary decreased consumption of the substance causing addiction. The appropriate dosage range is 0.1-500 milligrams daily, and especially 10-70 milligrams daily administered once or twice per day, depending as is usual on the exact mode of administration, the form in which it is administered, the indication to which the administration is directed, the subject involved and the body weight of the subject involved, and also the preference and experience of the doctor or veterinarian in charge. i.p. means intraperitoneally, which is a well-known route of administration. p.o. means peroral, which is a well-known administration route. The invention therefore comprises the following alone or in combination: The use of a compound as mentioned above in which the disease to be treated is pain, a disease in the central system, a disease caused by smooth muscle contraction, neurodegeneration , inflammation, symptoms of excessive use or withdrawal of chemical substances caused by the cessation of consumption of the chemical. The use as mentioned above in which a disease in the central system is Alzheimer's disease, Parkinson's disease, memory dysfunction or attention deficit hyperactivity disorder. The use as mentioned above, wherein the disease to be treated is excessive use or withdrawal symptoms of chemical substances caused by the discontinuation in the ingestion of the chemical, said excessive use of the chemical substance is smoking or the use of other products that contain nicotine, and withdrawal symptoms caused by the discontinuation of the use of nicotine-containing products. The method as mentioned above where pain is treated, a disease in the central or peripheral system, a disease caused by smooth muscle contraction, neurodegeneration, inflammation, symptoms of excessive use or withdrawal of chemical substances caused by the cessation of consumption of chemical substances, such as quitting smoking. The method as mentioned above in which are treated the symptoms of excessive use or withdrawal of chemical substances caused by the cessation of consumption of the chemical, such excessive use of chemical substance is smoking or the use of other products containing nicotine and withdrawal symptoms caused by cessation of use of products containing nicotine. A method as mentioned above in which a disease is treated in the central or peripheral system, said disease is Alzheimer's disease, Parkinson's disease, memory dysfunction or attention deficit hyperactivity disorder. The following examples will illustrate the invention in greater detail, however, they do not represent a limit.
EXAMPLES
General: All reactions involving reagents or intermediaries sensitive to air were carried out under nitrogen and in anhydrous solvents. Magnesium sulfate was used as a drying agent in the treatment processes and the solvents were evaporated under reduced pressure.
Method A (±) -1-Methyl-3-oxy- (3-pyridyl) -pyrrolidine (1a) A solution of 3-oxi- (3-pyridyl) -pyrrolidine (3.0 g, 18.3 mmol), acid Formic (25.3 g, 99%), formaldehyde (5.5 g, 37%) and water (50 ml) was stirred under reflux for 15 hours. The mixture was evaporated, and sodium hydroxide (60 ml, 4 M) was added, and the product was extracted twice with ethyl acetate (60 ml). The product was isolated as an oil. Yield 2.5 g, 77%.
(±) -1-Methyl-3-oxy- (3-pyridyl) -azetidinoxalic acid salt Prepared in accordance with method A. P.f. 166.9-170 ° C.
(+) - 1 -Methyl-3-oxy- (3-pyridyl) -piperidine (3a) Prepared according to method A. Isolated as an oil.
(±) -1-Methyl-3-oxi- (5-chloro-3-pyridyl) -pyrrolidone (4a) Prepared according to method A. Isolated as an oil.
Acid salt (±) -1-methyl-3-oxy- (5-chloro-3-pyridyl) -piperidine-fumaric acid
(5a) Prepared in accordance with method A. P.f. 137.2-139.4 ° C.
(±) -1 -Methyl-3-oxy- (2-chloro-3-pyridyl) -pperidine (6a) Prepared according to method A. Isolated as an oil.
Acid salt (±) -1-methyl-4-oxy- (3-pyridyl) -homopiperidinfumárico
(7a) Prepared in accordance with method A. P.f. 76-78 ° C. (±) -1-Methylene-4-oxy- (5-chloro-3-pyridyl) -homopiperidine-fumaric acid salt (8a) Prepared in accordance with method A. P.f. 113-116 ° C.
Method B (±) -3-Oxi- (3-pyridyl) -pyrrolidine (1 b) To a mixture of (±) -3-oxy- (3-pyridyl) -1-fer-butoxycarbonylpyrrolidine ( 16.0 g, 60.8 mmol) and dichloromethane (300 mL) was added trifluoroacetic acid (97 mL) and stirred for 6 hours followed by evaporation. Methanol (50 ml) was added and the solution was cooled on ice. Sodium hydroxide (10 g, 0.25 mol) was added slowly and the mixture was stirred for 15 hours. The volume of the solvent was reduced to 10 ml, and dichloromethane (30 ml) was added. The crude mixture was chromatographed on silica gel with dichloromethane, methanol and concentrated ammonia (89: 10: 1) and gave the title compound as an oil. Yield 5.0 g, 50%.
Salt of (±) -3-oxy- (3-pyridyl) -zetidintrifluoroacetic acid (2b) Prepared according to the method B. P.f. 151.8-152.7 ° C.
(±) -3-Oxy- (3-pyridyl) -piperidine (3b) Prepared in accordance with method B. Isolated as an oil.
Acid salt (±) - (5-chloro-3-pyridyl) -3-oxy-pyrrolidine-fumaric acid (4b) Prepared according to the method B. P.f. 141.7-143.2 ° C.
Acid salt (±) - (5-chloro-3-pyridyl) -3-oxy-piperidine-fumaric acid (5b) Prepared according to the method B. P.f. 170.5-172.7 ° C.
Acid salt (±) - (2-chloro-3-pyridyl) -3-oxy-pyrimidine (6b) Prepared according to the method B. P.f. 143.9-146.0 ° C.
(±) -4-Oxy- (3-pyridyl) -homopiperidn-fumaric acid salt (7b) Prepared according to the method B. P.f. 117-119 ° C.
(±) - (5-chloro-3-pyridyl) -4-oxy-homopiperidine (8b) Prepared in accordance with method B. Isolated as an oil.
Method C Diethylazodicarboxylate (16.7 g, 96 mmol) was added dropwise to a mixture of tetrahydrofuran (150 ml) and triphenylphosphine (25.2 g, 96 mmol) and stirred for 0.5 hour. (+) - 3-Hydroxy-1-yer-butoxycarbonylpyrrolidine (12.0 g, 64 mmol) was dissolved in tetrahydrofuran (50 ml) and added dropwise, followed by 3-hydroxypyridine (9.1 g, 96 mmol). The mixture was stirred for 15 hours at 40 ° C. The solvent was evaporated and sodium hydroxide (200 ml, 1 M) was added followed by extraction three times with diethyl ether (200 ml). The solvent was reduced to half the volume by evaporation, and the triphenylphosphine oxide was filtered. The crude mixture was chromatographed on silica gel with dichloromethane and methanol (25: 1). The title compound was obtained. Yield 16.1 g, 100%.
(±) -4-Oxi- (3-pyridyl) -1-tert-butoxycarbonylhomopiperidine Prepared in accordance with method C.
1-7er-butoxycarbonyl-azetidn-3-ol A mixture of azetidin-3-ol (7.0 g, 96 mmol) (SS Chattatarjee and DJ Triggle Chem. Commun. 93, (1968)), triethylamine (10.7 g, 106 mmol) and di-fer-butyl bicarbonate (21.0 g, 96 mmol) in dichloromethane (150 ml) was stirred for 15 hours. The crude mixture was evaporated and chromatographed on silica gel with dichloromethane and ethanol (4%). The title compound was obtained. Yield 12.9 g, 78%.
Claims (9)
1. - A compound represented by the general formula (I) any of its enantiomers or any mixture thereof, or a pharmaceutically acceptable salt thereof; wherein m is 1, 2 or 3; n is 1, 2 or 3; R represents hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, aryl or aralkyl; and R1 represents a 5-6 membered monocyclic heterocyclic group which may be substituted one or more times with substituents that are selected from the group consisting of alkyl, cycloalkyl, cycloalkylalkyl, alkenyl, alkynyl, alkoxy, cycloalkoxy, methylenedioxy, halogen, CF3 , OCF3, CN, amino, nitro, -COOR3, -CONR2R3, -NH-CO2R2, NHCO-R2, -OCO-NR2R3; wherein R2 and R3 independently represent hydrogen or alkyl; aryl optionally substituted one or more times with alkyl, cycloalkyl, cycloalkylalkylalkenyl, alkynyl, alkoxy, cycloalkoxy, methylenedioxy, halogen, CF3, OCF3, CN, amino and nitro; X-alkyl-Y-alkyl wherein X and Y independently represent O, S, NH, N-alkyl or Se; and alkyl is optionally substituted with alkoxy or thioalkoxy; -X- (alkyl) 0-aryl- wherein o is 0 or 1 and X represents O, S, NH, N-alkyl or Se; optionally substituted one or more times with alkyl, cycloalkyl, cycloalkylalkylalkenyl, alkynyl, alkoxy, cycloalkoxy, methylenedioxy, halogen, CF3, OCF3, CN, amino and nitro; monocyclic heterocyclic group -X- (alkyl) 0-5- or 6-membered wherein o is 0 or 1 and X represents O, S, NH, N-alkyl or Se; optionally substituted one or more times with alkyl, cycloalkyl, cycloalkylalkylalkenyl, alkynyl, alkoxy, cycloalkoxy, methylenedioxy, halogen, CF3, OCF3, CN, amino and nitro; a monocyclic 5- to 6-membered heterocyclic group optionally substituted one or more times with alkyl, cycloalkyl, cycloalkylalkyl, alkenyl, alkynyl, alkoxy, cycloalkoxy, methylenedioxy, halogen, CF3, OCF3, CN, amino and nitro; or R1 represents a bicyclic heterocyclic group, composed of a 5-6 membered monocyclic heterocyclic group fused to a benzene ring, and which may be substituted one or more times with substituents that are selected from the group consisting of alkyl, cycloalkyl, cycloalkylalkylalkenyl, alkynyl, alkoxy, alkoxy-alkoxy, cycloalkoxy, methylenedioxy, halogen, CF3, OCF3, CN, amino, nitro, aryl optionally substituted one or more times with alkyl, cycloalkyl, cycloalkylalkylalkenyl, alkynyl, alkoxy, cycloalkoxy, methylenedioxy, halogen, CF3, OCF3, CN, amino and nitro; and a 5-6 membered monocyclic heterocyclic group optionally substituted one or more times with alkyl, cycloalkyl, cycloalkylalkylalkenyl, alkynyl, alkoxy, cycloalkoxy, methylenedioxy, halogen, CF3, OCF3 CN, amino, and nitro.
2. - A compound of the formula (I), according to claim 1, further characterized in that R and R1 are attached to an azetidine, pyrrolidine, piperidine or homopiperidine.
3. A compound of the formula (I), according to claim 1, further characterized in that n is 1 and m is 1 or 2; R is hydrogen or C? -4 alkyl; and R1 represents a pyridyl or a substituted pyridyl.
4. A compound of the formula (I), according to claim 1, further characterized in that R1 is 3-pyridyl, 5-chloro-3-pyridyl, 2-cioro-3-pyridyl.
5. A compound of the formula (I), according to claim 1, said compound being: (±) -1-Methyl-3-oxy- (3-pyridyl) -pyrrolidine; (±) -1-Methyl-3-ox- (3-pyridyl) -azetidine; (±) -1-Methyl-3-oxy- (3-pyridyl) -piperidine; (+) - 1-Methyl-3-oxy- (5-chloro-3-pyridyl) -pyrrolidine; (±) -1-Methyl-3-oxi- (5-chloro-3-pyridyl) -piperidine; (±) -1-Methyl-3-ox- (2-chloro-3-pyridyl) -piperidine; (±) -1-Methyl-4-oxy- (3-pyridyl) -homopyperidine; (±) -1 -Methyl-4-oxy- (5-chloro-3-pyridyl) -homopiperidine; (±) -3-Oxy- (3-pyridyl) -pyrrolidine; (±) -3-Oxy- (3-pyridyl) -azetidine; (±) -3-Oxi- (3-pyridyl) -piperidine; (+) - (5-chloro-3-pyridyl) -3-oxy-pyrrolidine; (±) - (5-chloro-3-pyridyl) -3-oxi-piperidine; (±) - (2-chloro-3-pyridyl) -3-oxy-piperidine; (±) -4-Ox- (3-pyridyl) -homopiperidine; or (±) - (5-chloro-3-pyridyl) -4-oxy-homopyperidine; or a pharmaceutically acceptable salt thereof.
6. A pharmaceutical composition, comprising a therapeutically effective amount of a compound according to any of claims 1 to 5, or a pharmaceutically acceptable addition salt thereof, together with at least one pharmaceutically acceptable carrier or diluent.
7. The use of a compound according to any of claims 1 to 5, for the manufacture of a medicament for the treatment of a disease of a living animal, including a human, whose disease responds to the activity of modulators of nicotinic ACh receptor.
8. The use according to claim 7, wherein the disease to be treated is pain, a disease in the central nervous system, a disease caused by smooth muscle contraction, neurodegeneration, inflammation, symptoms of excessive use or abstinence from chemical substances caused by the cessation of consumption of the chemical substance such as quitting smoking.
9. The use of a compound according to claim 8, wherein a disease in the central nervous system is Alzheimer's disease, Parkinson's disease, memory dysfunction or hyperactivity disorder with attention deficit. SUMMARY OF THE INVENTION The present invention describes compounds represented by the general formula (I) any of its enantiomers or any mixture thereof, or a pharmaceutically acceptable salt thereof; wherein m is 1, 2 or 3; n is 1, 2 or 3; R represents hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, aryl or aralkyl; and R1 represents a 5-6 membered monocyclic heterocyclic group which may be substituted one or more times with substituents that are selected from the group consisting of alkyl, cycloalkyl, cycloalkylalkyl, alkenyl, alkynyl, alkoxy, cycloalkoxy, methylenedioxy, halogen, CF3 , OCF3, CN, amino, nitro, -COOR3, -CONR2R3, -NH-CO2R2, NHCO-R2, -OCO-NR2R3; wherein R2 and R3 independently represent hydrogen or alkyl; aryl optionally substituted one or more times with alkyl, cycloalkyl, cycloalkylalkyl alkenyl, alkynyl, alkoxy, cycloalkoxy, methylenedioxy, halogen, CF3, OCF3, CN, amino and nitro; -X-alkyl-Y-alkyl wherein X and Y independently represent O, S, NH, N-alkyl or HE; and alkyl is optionally substituted with alkoxy or thioalkoxy; -X- (alkyl) 0-aryl- wherein 0 is 0 or 1 and X represents O, S, NH, N-alkyl or Se; optionally substituted one or more times with alkyl, cycloalkyl, cycloalkylalkylalkenyl, alkynyl, alkoxy, cycloalkoxy, methylenedioxy, halogen, CF3, OCF3, CN, amino and nitro; monocyclic heterocyclic group -X- (alkyl) 0-5- or 6- members in which o is 0 or 1 and X represents O, S, NH, N-alkyl or Se; optionally substituted one or more times with alkyl, cycloalkyl, cycloalkylalkylalkenyl, alkynyl, alkoxy, cycloalkoxy, methylenedioxy, halogen, CF3, OCF3, CN, amino and nitro; a monocyclic 5- to 6-membered heterocyclic group optionally substituted one or more times with alkyl, cycloalkyl, cycloalkylalkyl, alkenyl, alkynyl, alkoxy, cycloalkoxy, methylenedioxy, halogen, CF3, OCF3, CN, amino and nitro; or R1 represents a bicyclic heterocyclic group, composed of a 5- to 6-membered monocyclic heterocyclic group fused to a benzene ring, and which may be substituted one or more times with substituents that are selected from the group consisting of alkyl, cycloalkyl, cycloalkylalkylalkenyl, alkynyl, alkoxy, alkoxy-alkoxy, cycloalkoxy, methylenedioxy, halogen, CF3, OCF3, CN, amino, nitro, aryl optionally substituted one or more times with alkyl, cycloalkyl, cycloalkylalkylalkenyl, alkynyl, alkoxy, cycloalkoxy, methylenedioxy, halogen, CF3, OCF3, CN, amino and nitro; and a 5- to 6-membered monocyclic heterocyclic group optionally substituted one or more times with alkyl, cycloalkyl, cycloalkylalkylalkenyl, alkynyl, alkoxy, cycloalkoxy, methylenedioxy, halogen, CF3, OCF3 CN, amino and nitro; The compounds of the invention are useful as nicotinic ACh receptor ligands.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DK1259/97 | 1997-11-05 | ||
PAPA199800850 | 1998-06-26 |
Publications (1)
Publication Number | Publication Date |
---|---|
MXPA00004396A true MXPA00004396A (en) | 2001-05-17 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6392045B1 (en) | 9-azobicyclo[3.3.1] non-2-ene derivatives as cholinergic ligands at nicotinic ACH receptors | |
RU2186780C2 (en) | Derivative of 8-azabicyclo[3,2,1]oct-2-ene, methods of its synthesis, pharmaceutical composition | |
US6352995B1 (en) | Spiro-quinuclidine derivatives, their preparation and use | |
US20070161614A1 (en) | Pyridylether derivatives, their preparation and use | |
EP0984943B1 (en) | Azacyclooctane and heptane derivatives, their preparation and usein therapy | |
MXPA00004396A (en) | Azaring-ether derivatives and their use as nicotinic ach receptor modulators | |
MXPA99011081A (en) | 8-azabicyclo(3,2,1)oct-2-ene and octane derivatives as cholinergic ligands at nicotinic ach receptors |